In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
|Articles|January 1, 1997
The American Journal of Managed Care
- January 1997
- Volume 3
- Issue 1
Patterns of Anti-Inflammatory Therapy in the Post-Guidelines Era: A Retrospective Claims Analysis of Managed Care Members
Advertisement
Articles in this issue
over 29 years ago
Implications of Managed Care Denials for Pediatric Inpatient Careover 29 years ago
Cost-Effectiveness of Sumatriptan in a Managed Care PopulationAdvertisement
Related to this article
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
A survivor shares axi-cel therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improves QOL.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Advertisement
Advertisement